TORONTO, June 22,
2023 /CNW/ - MediPharm Labs Corp. (TSX: LABS)
(OTCQX: MEDIF) (FSE: MLZ) ("MediPharm", "MediPharm Labs" or
the "Company"), a pharmaceutical company specialized in
precision-based cannabinoids, today announced that, at the request
of the Company's board of directors and following the
recommendation of the audit committee, the Company's board of
directors have accepted the resignation of KPMG LLP as the auditor
of the Company effective June 5, 2023
and approved the appointment of MNP LLP as successor auditor
effective June 5, 2023.
After completion of the previously announced acquisition of all
of the issued and outstanding common shares of VIVO Cannabis Inc.
("VIVO") effective April 1, 2023,
MediPharm Labs undertook a review of the two incumbent auditors,
being KPMG LLP, MediPharm's former auditor, and MNP LLP, VIVO's
former auditor. Following its review, the Company selected MNP LLP
to appoint as its auditor going forward.
In accordance with National Instrument 51-102 – Continuous
Disclosure Obligations ("NI 51-102"), the Company has filed a
Notice of Change of Auditor, together with response letters from
KPMG LLP and MNP LLP on SEDAR under the Company's profile at
www.sedar.com. There were no "reportable events," as such term is
defined in NI 51-102.
About MediPharm Labs
Founded in 2015, MediPharm Labs specializes in the development
and manufacture of purified, pharmaceutical-quality cannabis
concentrates, active pharmaceutical ingredients (API) and advanced
derivative products utilizing a Good Manufacturing Practices
certified facility with ISO standard-built clean rooms. MediPharm
Labs has invested in an expert, research driven team,
state-of-the-art technology, downstream purification methodologies
and purpose-built facilities with five primary extraction lines for
delivery of pure, trusted and precision-dosed cannabis products for
its customers. Through its wholesale and white label platforms,
MediPharm Labs formulates, develops (including through sensory
testing), processes, packages and distributes cannabis extracts and
advanced cannabinoid-based products to domestic and international
markets.
In 2021, MediPharm Labs received a Pharmaceutical Drug Establish
License from Health Canada, becoming the only company in
North America to hold a domestic
Good Manufacturing License for the extraction of natural
cannabinoids. The Company carries out its operations in compliance
with all applicable laws in the countries in which it operates.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/medipharm-labs-announces-change-of-auditor-301858623.html
SOURCE MediPharm Labs Corp.